Genentech acquires a portfolio of CDK inhibitors
Genentech is paying $850 million upfront for Regor Pharmaceuticals’ portfolio of CDK inhibitors, taking ownership of a breast cancer candidate that has shown signs of single-agent efficacy in patients failed by existing options
Regor, a Chinese-American biotech, presented phase 1a results on its next-generation CDK inhibitor late last year. The biotech designed the drug candidate to have high potency against CDK4, additional activity versus CDK2 and selectivity against CDK6. Those features are intended to overcome resistance to CDK4/6 inhibition and reduce hematologic toxicity.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins